1、Lu LJ*, Wallace DJ, Weisman M, et al.. Male SLE: A Review of Sex Disparities in this Disease.. LUPUS,2010;9:119-129
2、Lu LJ*, Wallace DJ, Navarra SV, et al.. Lupus Registries: Evolution and Challenges.. Semin Arthritis Rheum,2010;39(4):224-245
3、Lu LJ*, Bao CD, Dai Min, et al.. Multicenter, randomized, double-blind, controlled trial of treatment of active rheumatoid arthritis with T-614 compared with methotrexate.. Arthritis Rheum,2009;61(7):979-87
4、Zhang CY, Lu LJ*, Li FH, et al.. Evaluation of risk factors that contribute to high prevalence of premature atherosclerosis in Chinese premenopausal systemic lupus erythematosus patients.. J Clin Rheumatol.,2009;15(3):111-6.
5、Du F, Lu LJ, Fu Q, et al.. T-614, a novel immunomodulator, attenuates joint inflammation and articular damage in collagen-induced arthritis.. Arthritis Res Ther.,2008;10(6):R136
6、Lu LJ*, Teng JL, Bao CD, et al.. Safety and efficacy of T-614 in the treatment of patients with active rheumatoid arthritis: a double blind, randomized, placebo-controlled and multicenter trial.. Chin Med J,2008;121(7):615-9.
7、Zou YQ, Lu LJ#, Li SJ, et al.. The levels ofmacrophage migration inhibitory factor as an indicator of disease activity and severity in adult-onset Still's disease.. Clin Biochem.,2008;41(7-8):519-24.
8、Lu LJ#,Zou YQ,Gou GM,et al.. Outcome of lupus renal disease in the past two decades: a report from China.. APLAR Journal of Rheumatology,2006;9;347-352
9、Lu Liangjing#, Chen Shunle, Gu Yueying, et al.. Transfection,overexpression and clinical application of the human60-kDa Ro/SSA autoantigens in HEp-2 cells.. Chin Med J,2003;116（3）；281-283.
|
